香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Technology Holdings Limited 中康科技控股有限公司 （前稱為Sinohealth Holdings Limited中康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：2361） 建議修訂現有章程大綱及章程細則及 採納新章程大綱及章程細則 本公告由中康科技控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）根據香港聯合 交易所有限公司證券上市規則（「上市規則」）第13.51(1)條作出。 本公司董事（「董事」）會（「董事會」）建議修改本公司現有的第四次經修訂及重述章程大綱及 章程細則（「現有章程大綱及章程細則」），並採納本公司第五次經修訂及重述章程大綱及章 程細則（「新章程大綱及章程細則」），以取代及摒除現有章程大綱及章程細則。 建議修訂旨在(i)使現有章程大綱及章程細則符合有關混合會議和電子投票以及上市發行人 以電子方式傳播公司通訊的最新監 ...

Financial Performance - Revenue for the year ended December 31, 2025, was RMB 419,090,000, representing a 3.8% increase from RMB 403,728,000 in 2024[3] - Operating profit increased by 19.0% to RMB 91,621,000 in 2025 from RMB 76,985,000 in 2024[3] - Gross profit margin improved to 59.4% in 2025, up from 57.8% in 2024, indicating enhanced operational efficiency[3] - Net profit decreased by 15.5% to RMB 94,499,000 in 2025 compared to RMB 111,823,000 in 2024[3] - Total assets reached RMB 866,074,000 in 2025, an increase from RMB 810,896,000 in 2024[6] - The company achieved a revenue of RMB 419.1 million, representing a year-on-year growth of 3.8%[30] - Revenue from commercial solutions reached RMB 273.2 million, accounting for 65.2% of total revenue, while data-driven releases and activities generated RMB 144.8 million, representing 34.6% of total revenue[50] - The company's gross profit increased by approximately 6.8% to RMB 249.1 million, with a gross margin rising to 59.4% from 57.8% in the previous year[53] - Sales costs decreased by approximately 0.3% to RMB 170.0 million, representing 40.6% of total revenue, due to improved operational efficiency[51] - Other income and gains fell by approximately 38.1% to RMB 27.8 million, primarily due to reduced interest income and foreign exchange losses[55] Strategic Focus and Development - The company has shifted its strategic focus to becoming an AI technology service provider based on health industry data and resources[7] - Significant investments were made in AI technology development, particularly in the "Zhuo Mu Niao" medical model and "Tian Gong No. 1" decision-making model[8] - The company aims to become a leading digital technology company in the life sciences sector by 2026, focusing on AI and healthcare integration[12] - The company has upgraded its strategic positioning to an AI technology service company based on health industry data elements and ecological resources as of December 2025[18] - The company aims to optimize its internal management system to adapt to the demands of the AI era, promoting a customer-centric and innovative organizational culture[10] - The company aims to deepen the commercialization solutions for healthcare industry participants, focusing on AI applications as a high-potential emerging business[20] - The company is transitioning from "digital technology" to "AI technology services," positioning itself as a leader in the AI-driven health industry[43] AI Applications and Innovations - The company has successfully deployed AI-driven solutions across various business segments, enhancing operational efficiency and service standardization[8] - The company has launched new AI applications, termed "AI+", targeting marketing, healthcare, pharmacy, and health management, demonstrating significant market potential[19] - The company has embedded AI technology into existing products and introduced new intelligent applications, enhancing business operations and commercializing AI applications[17] - The company is committed to strengthening its core technology and continuously iterating its large models, "Zhuo Mu Niao" and "Tian Gong Yi Hao" for complex applications[12] - The "Tiangong No. 1" decision-making model has achieved a 38% year-on-year increase in demand capacity and a 28% improvement in processing time efficiency[26] - The company has established a "dual-engine" AI core system, integrating high-quality data and professional knowledge, which has led to a significant competitive advantage in the healthcare sector[22] - The company has developed a "Zhongkang Medical Health All-Scenario Intelligent Platform," which includes an intelligent assistant center and a creative platform for customized AI solutions[23] Market and Industry Insights - The Chinese pharmaceutical market size in 2025 was 200.33 billion CNY, showing a year-on-year decline of 1.4%[14] - The company recognizes the shift from passive growth to proactive evolution in the pharmaceutical market, driven by increasing health demands and innovative supply-side reforms[14] - The health fast-moving consumer goods market is identified as having significant potential, leading to the establishment of a Contract Sales Organization (CSO) to connect quality manufacturers with retail pharmacies[42] Research and Development - R&D expenses have continued to grow, focusing on computing infrastructure and high-end talent recruitment, ensuring technological leadership[24] - The group's research and development costs increased to RMB 73,566,000 in 2025 from RMB 64,771,000 in 2024, reflecting a focus on innovation[92] Corporate Governance and Compliance - The company has adopted corporate governance principles and complied with applicable codes, ensuring effective internal leadership and strategy planning[110] - The audit committee consists of three independent non-executive directors, with Mr. Wei Bin serving as the chairman[114] - The company is committed to maintaining high corporate governance standards as outlined in the corporate governance code[114] Cash and Assets Management - Cash and cash equivalents totaled approximately RMB 233.3 million as of December 31, 2025, representing an increase of about 266.2% compared to the previous year, attributed to a revised cash management strategy[63] - The group maintained a strong cash position with no short-term or long-term bank borrowings as of December 31, 2025, except for lease liabilities totaling approximately RMB 8.0 million[64] - The asset-liability ratio as of December 31, 2025, was approximately 15.0%, up from 14.4% as of December 31, 2024[65] Employee and Leadership Structure - The group employed a total of 785 full-time employees as of December 31, 2025, an increase from 768 employees the previous year, with employee costs amounting to approximately RMB 168.8 million, up about 6.8%[71] - The executive directors include Mr. Wu Yushu and Ms. Wang Lifang, indicating a stable leadership structure[119] Future Strategies - Future strategies include optimizing the "Zhuomuniao" and "Tiangong No. 1" AI models to enhance data quality and support AI model optimization[44] - The company plans to develop various AI-driven products to support clients' performance growth, focusing on both outpatient and inpatient markets[45] - Strategic investments and acquisitions will be pursued to acquire key technologies and resources, accelerating the commercialization of AI in healthcare[47]

EF001 EF001 其他信息 其他信息 不適用 發行人董事 於本公告日期，執行董事為吳鬱抒先生及王莉芳女士；非執行董事為付海濤先生；及獨立非執行董事為王丹舟女士、徐海音女士及 魏斌先生。 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | --- | --- | | | 股票發行人現金股息公告 | | 發行人名稱 | 中康科技控股有限公司 | | 股份代號 | 02361 | | 多櫃檯股份代號及貨幣 | 不適用 | | 相關股份代號及名稱 | 不適用 | | 公告標題 | 截至2025年12月31日止年度之末期股息 | | 公告日期 | 2026年3月27日 | | 公告狀態 | 新公告 | | 股息信息 | | | 股息類型 | 末期 | | 股息性質 | 普通股息 | | 財政年末 | 2025年12月31日 | | 宣派股息的報告期末 | 2025年12月31日 | | 宣派股息 | 每 股 0.0712 HKD | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Technology Holdings Limited 中康科技控股有限公司 （前稱為Sinohealth Holdings Limited中康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：2361） 董事會會議日期 中康科技控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，本公司將於二零 二六年三月二十七日（星期五）舉行董事會會議，藉以（其中包括）考慮及批准本公司及其附 屬公司截至二零二五年十二月三十一日止年度之年度業績及其發佈，並考慮建議派發末期 股息（如有）。 承董事會命 中康科技控股有限公司 主席 吳鬱抒 香港，2026年3月13日 於本公告日期，執行董事為吳鬱抒先生及王莉芳女士；非執行董事為付海濤先生；及獨立非執行董 事為王丹舟女士、徐海音女士及魏斌先生。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中康科技控股有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02361 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.01 USD | | 20,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | | 0.01 USD | | 20,000,000 | 本月底法定/註冊股本總額： USD 20,000 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Technology Holdings Limited 中康科技控股有限公司 （前稱為中康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：2361） 有關公眾持股量狀況的公告 茲提述中康科技控股有限公司（「本公司」）日期為2022年12月5日有關採納股份獎勵計劃的 公告及本公司日期為2026年1月21日及2026年2月9日有關本公司公眾持股量狀況的公告 （「該等公告」）。除另有界定者外，本公告所用詞彙與該等公告所界定者具有相同涵義。 董事會宣佈，就董事會所深知、全悉及確認，於本公告日期，本公司的公眾持股量約為 16.45%，低於上市規則第13.32B(1)條所規定25%的最低指定公眾持股量（「初始指定門 檻」）。其原因為39,958,477股股份（佔於本公告日期本公司已發行股本總額的約 8.84%）為 未授予股份獎勵，並由富途信託有限公司作為股份獎勵計劃之受託人持有，該 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 – 1 – Sinohealth Technology Holdings Limited 中康科技控股有限公司 （前稱為中康控股有限公司） （於開曼群島註冊成立的有限公司） （股份代號：2361） 更改公司名稱及股份簡稱 茲提述中康科技控股有限公司（前稱為中康控股有限公司）（「本公司」）日期為2025年12月 24日的公告及本公司日期為2025年12月31日的通函（「該通函」），內容有關（其中包括）建 議更改公司名稱，以及本公司日期為2026年1月15日的公告，內容有關於2026年1月15日 舉行的股東特別大會投票表決結果。除非文義另有所指，否則本公告所用詞彙與該通函所 界定者具有相同涵義。 更改公司名稱 董事會欣然宣佈，本公司的英文名稱已由「Sinohealth Holdings Limited」更改為「Sinohealth Technology Holdings Limited」，而本公司的中文雙重外 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示不會就因本公告全部或任何部分內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 Sinohealth Holdings Limited 中康控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2361） 有關公眾持股量狀況的補充公告 茲提述本公司日期為2026年1月21日有關本公司公眾持股量狀況的公告及本公司日期為 2026年1月15日有關根據股份獎勵計劃授出股份獎勵的公告（「該等公告」）。除另有界定者 外，本公告所用詞彙與該等公告所界定者具有相同涵義。 董事會謹此澄清，截至該公告日期，本公司的公眾持股量為16.45%，低於上市規則第 13.32B(1)條所規定25%的最低指定公眾持股量（「初始指定門檻」）。其原因為39,958,477股 股份（佔截至該公告日期本公司已發行股本總額的約 8.84%）為未授予股份獎勵，並由富途 信託有限公司作為股份獎勵計劃之受託人持有，該等股份並未計入本公司之公眾持股量。 結合本公司戰略發展及合資格參與者的績效完成情況，本公司預期將於未來三年內 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2026年1月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | 中康控股有限公司 | | | | 呈交日期: | 2026年2月5日 | | | I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02361 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.01 USD | | 20,000,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,000,000, ...

Core Viewpoint - Zhongkang Holdings (02361) announced that its public float is approximately 16.45%, which is below the minimum requirement of 25% as stipulated by Listing Rule 8.08(1)(a) [1] Group 1 - The company's public holding has decreased to 16.45% [1] - This level of public holding is non-compliant with the listing regulations [1]